JOHANNESBURG and PITTSBURGH, April 16, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) announced that its subsidiary, Mylan Laboratories Ltd., a leading manufacturer of antiretroviral (ARV) drugs, has delivered, through its South African-based subsidiary Mylan (Proprietary) Limited (Mylan Limited), stock of the highly anticipated "one pill once a day" ARV combination to the South African National Department of Health's Gauteng depot. Mylan was selected in November 2012 to be one of the leading suppliers of ARV drugs to the National Department of Health for the tender period January 1, 2013 to December 31, 2014.
In November 2012, the South African Minister of Health, Dr. Aaron Motsoaledi, announced that, "As from April next year, patients who are on ARV treatment will no longer have to take three tablets, but only need one tablet per day." On April 8, 2013, Dr. Motsoaledi launched the FDC ARVs at Phedisong 4 Community Health Clinic. "From June onwards, all other stable, non-complicated patients will be switched to FDCs after consultation with their clinicians," he explained.
To support the National Department of Health's commitment to providing this option to people living with HIV/AIDS in South Africa, Mylan has delivered stock ahead of the deadline. Additionally, as part of Mylan's efforts to further consumer education and support anti-counterfeit measures, Mylan has partnered with TrustaTAG Systems. TrustaTAG Systems developed PharmaTAG?, a patented system using unique two-dimensional tags that enable consumers to use their mobile phones to simply scan the TAG on a product and gain access to patient-information leaflets, pack shots, company information and other items. The TrustaTAG offering allows for a company to display information in multiple languages, which in the South Africa context is hugely beneficial. TrustaTAG? ensures compliance with the Consumer Protection Act and the Medicines Act, ensuring that patients receive all necessary information in an understandable language.
"Availability of the 'one pill once a day' ARV combination is another important step in the fight against HIV/AIDS in South Africa. Simplifying treatment options, with the added benefit of reduced pressure on logistics and supply systems, is the first step towards greater access to those in need of these life-saving medicines," said Anirudh Deshpande, Head of Emerging Markets and Exports for Mylan Laboratories Ltd.
Ian Puttergill, CEO of TrustaTAG Systems commented, "We are really excited and proud to work with a market-leading company such as Mylan, which has shown incredible drive and passion to provide patients access to vital product information through innovative channels such as TrustaTAG?."
Mylan supplies ARV drugs to more than 120 countries around the world, and nearly 40% of HIV/AIDS patients receiving treatment in developing countries depend on a Mylan ARV product. Mylan recently entered the South African market with a comprehensive portfolio of ARV drugs, consisting of first- and second-line adult and pediatric therapies, including several dual and triple FDCs.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
CONTACT: Nina Devlin (Media), 724.514.1968; Kris King (Investors), 724.514.1813
Web Site: http://www.mylan.com